The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Liver resectability following S-1+L-OHP with cetuximab as the first-line treatment of unresectable liver limited metastases from KRAS exon 2 wild-colorectal cancer in Japanese patients (KSCC 1002).
 
Yuji Miyamoto
No Relationships to Disclose
 
Yasunori Emi
Honoraria - Merck Serono; Taiho Pharmaceutical; Yakult Honsha
 
Shoji Tokunaga
No Relationships to Disclose
 
Toru Beppu
No Relationships to Disclose
 
Yoshihiro Kakeji
Honoraria - Merck Serono; Taiho Pharmaceutical; Yakult Honsha
 
Eiji Oki
Honoraria - Merck Serono; Taiho Pharmaceutical; Yakult Honsha
 
Hiroshi Saeki
No Relationships to Disclose
 
Shinichiro Mori
No Relationships to Disclose
 
Masafumi Inomata
No Relationships to Disclose
 
Yoshito Akagi
Honoraria - Merck Serono; Taiho Pharmaceutical; Yakult Honsha
 
Hideo Baba
Honoraria - Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical; Yakult Honsha
 
Shoji Natsugoe
Honoraria - Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical
 
Yutaka Ogata
No Relationships to Disclose
 
Yoshihiko Maehara
Honoraria - Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Merck Serono; Taiho Pharmaceutical
Research Funding - Merck Serono; Taiho Pharmaceutical; Yakult Honsha